lopinavir/ritonavir in COVID-19 mild to moderate - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results Hung et al., 2020 (REV) 2.11 [0.04; 108.31]
Solaymani-Dodaran, 2021 (REV) 0.82 [0.44; 1.51]
0.84 [0.46 ; 1.54 ] Hung et al., 2020 (REV), Solaymani-Dodaran, 2021 (REV) 2 0% 500 moderate not evaluable clinical improvementdetailed results Hung et al., 2020 (REV) 0.26 [0.11; 0.60]
0.26 [0.11 ; 0.60 ] Hung et al., 2020 (REV) 1 0% 127 NA not evaluable clinical improvement (time to event analysis only)detailed results Hung et al., 2020 (REV) 0.26 [0.11; 0.60]
Solaymani-Dodaran, 2021 (REV) 1.06 [0.85; 1.33]
0.55 [0.14 ; 2.24 ] Hung et al., 2020 (REV), Solaymani-Dodaran, 2021 (REV) 2 90% 507 moderate not evaluable mechanical ventilationdetailed results Solaymani-Dodaran, 2021 (REV) 0.62 [0.32; 1.18]
0.62 [0.32 ; 1.18 ] Solaymani-Dodaran, 2021 (REV) 1 0% 373 NA not evaluable viral clearance detailed results Hung et al., 2020 (REV) 0.23 [0.10; 0.54]
0.23 [0.10 ; 0.54 ] Hung et al., 2020 (REV) 1 0% 127 NA not evaluable viral clearance (time to event analysis only)detailed results Hung et al., 2020 (REV) 0.23 [0.10; 0.54]
0.23 [0.10 ; 0.54 ] Hung et al., 2020 (REV) 1 0% 127 NA not evaluable viral clearance by day 14detailed results ELACOI (Lopinavir/ritonavir), 2020 (REV) 0.54 [0.12; 2.48]
0.54 [0.12 ; 2.48 ] ELACOI (Lopinavir/ritonavir), 2020 (REV) 1 0% 69 NA not evaluable viral clearance by day 7detailed results ELACOI (Lopinavir/ritonavir), 2020 (REV) 0.92 [0.35; 2.47]
0.92 [0.35 ; 2.47 ] ELACOI (Lopinavir/ritonavir), 2020 (REV) 1 0% 69 NA not evaluable ICU admissiondetailed results Solaymani-Dodaran, 2021 (REV) 0.81 [0.46; 1.44]
0.81 [0.46 ; 1.44 ] Solaymani-Dodaran, 2021 (REV) 1 0% 373 NA not evaluable severe COVID-19 occurrencedetailed results ELACOI (Lopinavir/ritonavir), 2020 (REV) 3.28 [0.79; 13.64]
3.28 [0.79 ; 13.64 ] ELACOI (Lopinavir/ritonavir), 2020 (REV) 1 0% 69 NA not evaluable serious adverse eventsdetailed results Hung et al., 2020 (REV) 4.28 [0.14; 130.10]
4.28 [0.14 ; 130.10 ] Hung et al., 2020 (REV) 1 0% 127 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-16 18:16 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 90
- treatments: 509
- roots T: 290